Insulin human (recombinant) is under clinical development by Elgan Pharma and currently in Phase III for Malabsorption Syndrome. According to GlobalData, Phase III drugs for Malabsorption Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Insulin human (recombinant) LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Insulin human (recombinant) overview
NTRA-2112 is under development for the treatment of malabsorption syndromes in perterm infants. The drug candidate is administered orally. It is an insulin formulation with excipients which are approved for infant consumption. It is developed based on a technology which formulates insulin powder for reconstitution.
Elgan Pharma overview
Elgan Pharma is a neonatology-focused company that develops a technology targeted at the prevention of visual impairment in preterm infants. It is headquartered in Nazareth, HaZafon, Israel.
For a complete picture of Insulin human (recombinant)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
